ACE inhibitors for kidney disease

June 1996

You'll see more physicians using ACE inhibitors for kidney disease...even in patients who don't have high blood pressure.

We've known that Capoten and other ACE inhibitors slow the progression of kidney disease in patients with diabetes.

Now researchers are finding that ACE inhibitors also help patients with renal insufficiency caused by other factors.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

HOME blood pressure monitoring
Obesity & Weight Loss Lots of patients are asking about Redux (dexfenfluramine)
Obesity & Weight Loss The biggest concern with Redux is an increased risk of primary pulmonary hypertension
Dermatology Lamisil (terbinafine) TABLETS for treating fungal nail infections
Serzone (nefazodone) probably causes less sexual dysfunction than SSRIs
Paxil (paroxetine) for panic disorder and obsessive compulsive disorder (OCD)
Multiple Sclerosis Avonex (interferon beta-1a), the new treatment for multiple sclerosis (MS)
Infectious Diseases new 3-day Cipro Cystitis Pack
Infectious Diseases Bactroban Nasal (mupirocin ointment) to reduce the spread of MRSA
Infectious Diseases Maxipime (MAXI-peem, cefepime), the first "fourth-generation" injectable cephalosporin
estrogen for postpartum depression
patient compliance with their new protease inhibitor, Norvir (ritonavir)
test themselves for HIV using the new Confide home testing service
ACE Inhibitors new ACE inhibitor, Mavik (trandolapril)
ACE Inhibitors ACE inhibitors for kidney disease
positive side to the recent news about pharmacists who missed common drug interactions